jump to navigation

MBBP Client MindChild Medical, Inc. Receives FDA Clearance of Fetal Heart Monitor 01/26/2017

Posted by Morse, Barnes-Brown Pendleton in Client News, Medical Devices.
Tags: , , , , , , , , ,
add a comment

MindChild Medical, Inc., a client of MBBP, has received FDA clearance for its Pre-Marketing Notification (510(k)) for its MERIDIAN™ M110 non-invasive fetal heart monitor. The FDA clearance will enable MindChild to enter the U.S. market with MERIDIAN™.

MindChild’s MERIDIAN™ M110 Fetal Monitoring System is an intrapartum fetal monitor that externally measures and displays fetal heart rate, maternal heart rate, and uterine contractions.

MindChild was founded in 2008 and is a privately funded medical device company. To learn more about the MERIDIAN™ device and MindChild, read the full press release.

Congratulations to MindChild on this achievement!

Interview with MBBP Client Valeritas Included in Wall Street Transcript Medical Devices Report 08/09/2016

Posted by Morse, Barnes-Brown Pendleton in Client News, Intellectual Property, Life Sciences, Medical Devices.
Tags: , , , , , , , , , , , ,
add a comment

The most recent Wall Street Transcript Medical Devices Report includes an interview with Valeritas, Inc.’s CEO, John Timberlake.  Timberlake discusses in detail Valeritas’s V-Go Disposable Insulin Delivery Device. The V-Go is a wearable basal-bolus insulin delivery device that allows patients to deliver insulin at a continuous preset basal rate, with bolus delivery as needed.  The V-Go has been cleared for use in the United States and in Europe.  big valThe fact that V-Go is a wearable product with scheduled insulin delivery enables patients to more easily go about their daily routines without having to stop to deliver insulin, and also allows them to discreetly deliver insulin during mealtimes without drawing attention to the act.

Valeritas is a commercial-stage medical technology company that develops new Type II diabetes technology products aimed at improving the lives of patients with Type II diabetes.  For more information about Valeritas and its V-Go product, read the full interview with The Wall Street Transcript.

MBBP Client Valeritas, Inc. Announced Positive Results for V-Go® Disposable Insulin Delivery Device 06/16/2016

Posted by Morse, Barnes-Brown Pendleton in Client News.
Tags: , , , , ,
add a comment

big valMBBP client Valeritas, Inc. has recently announced positive results for four studies on their flagship product. Valeritas is a commercial-stage medical technology company focused on developing innovative solutions to improve health and quality of life of people with Type 2 diabetes.

Their flagship product is the V-Go® Disposable Insulin Delivery Device which is a small, wearable, disposable insulin delivery solution for the delivery of basal-bolus insulin therapy in adults with Type 2 diabetes.

The four studies were as followed:

Study 1: Evaluating the Impact on Diabetes Control with V-Go® For Patients with Diabetes not Achieving Optimal Control: A Retrospective Cohort Analysis in a Large Endocrine and Specialized Diabetes System

Study 2: Evaluating V-Go® In Patients 65 Years of Age or Older with Poorly Controlled Diabetes: A Health Outcome and Economic Analysis from an Endocrine and Diabetes Specialty System

Study 3: Optimizing Insulin Therapy in Older Adults in Long-Term Care: A Com   parative Retrospective Analysis of V-Go® vs. Standard of Care

Study 4: Improved Glycemic Control in Patients with Type 2 Diabetes Switching to the V-Go® Insulin Delivery Device: A Prospective Study Utilizing Continuous Glucose Monitoring

These studies showed that when using, or switching to V-Go®, patients with diabetes experienced improved glycemic control, a reduction in A1C and cost savings when compared to comparison treatments. Overall, Dr. David Sutton remarks, “The studies that I am involved with provide data that continues to support the real-world clinical value of using V-Go® in patients that require insulin. Importantly, the data presented at ADA shows the value of V-Go® in older patients that require both a clinically-effective and cost-effective therapy.”

Great work, Valeritas, Inc.!

For more information, read Valeritas press release.

MBBP Client Valeritas Files IPO 02/17/2015

Posted by Morse, Barnes-Brown Pendleton in Client News.
Tags: , , , , , ,
add a comment

Valeritas, Inc.

On February 12, 2015, MBBP client Valeritas, Inc., a medical technology company focused on the development and commercialization of innovative drug delivery solutions, filed for a $90 million IPO.

The filing with the SEC arrives one week after insulin pump maker Asante Solutions postponed its proposed $49 million offering.

Valeritas markets a disposable device that delivers basal-bolus insulin therapy for Type 2 diabetes.

More details can be found here or visit www.valeritas.com.

MBBP’s Joanna Brougher 2014 National Law Journal Rising Star 09/02/2014

Posted by Morse, Barnes-Brown Pendleton in Attorney News, Intellectual Property, Life Sciences, MBBP news, Medical Devices.
Tags: , , , , , ,
add a comment

9-2-2014 10-08-43 AM MBBP’s Joanna Brougher was selected for the 2014 National Law Journal’s list of Boston’s Rising Stars. The National Law Journal Rising Stars program recognizes the region’s 40 most promising lawyers age 40 and under.  Joanna graduated from the University of Rochester with a B.S. in Microbiology, a B.A. in German, and a masters in public health. Joanna received her J.D. from Boston College Law School in 2008.  She is a biotech, pharma, medical device and intellectual property consultant, and is also a adjunct lecturer at Harvard School of Public Health where she teaches a course on intellectual property and health technologies.

Congrats, Joanna!

More info on Boston’s Rising Stars

Valeritas Financing Round Tops VC Deals for Second Half of 2011 04/02/2012

Posted by Morse, Barnes-Brown Pendleton in Client News.
Tags: , , ,
add a comment

In September 2011, MBBP client Valeritas, Inc., a medical technology company focused on the development and commercialization of innovative drug delivery solutions, announced it had completed a significant Series C round of financing of $150 million. According to a recent listing by Fierce Medical Devices this Series C Financing was the top venture capital deal in the medical devices space in the second half of 2011. Other companies to make this list include Intuity Medical ($76M), HeartFlow ($65M) , and AcuFocus ($65M), all three based in California.

Valeritas has planned to use the funding to support the commercialization of its V-Go disposable insulin delivery device, an alternative to multiple daily insulin injections.

Congratulations Valeritas!

%d bloggers like this: